Ultragenyx Pharmaceutical
Treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. Learn more
Launch date
Employees
Market cap
€4.8b
Enterprise valuation
€4.2b (Public information from Sep 2024)
Share price
$58.78 RARE
Novato California (HQ)
Authorizing premium user...